MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics Target Price

Where could MLTX trade next? Consensus target price: $48.

Get informed when a big investor buys or sells

+ Follow

Share Price

$15.01

Average Target Price

$47.50

216.5% upside

2 analysts in the last 4 months

High: $50 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-13	H.C. Wainwright	$50	233.1% upside
2026-05-11	H.C. Wainwright	$45	199.8% upside
2026-02-24	Oppenheimer	$35	133.2% upside
2026-01-14	Goldman Sachs	$10	33.4% downside
2026-01-09	H.C. Wainwright	$32	113.2% upside
2026-01-09	UBS	$24	59.9% upside
2026-01-08	UBS	$45	199.8% upside
2025-11-21	H.C. Wainwright	$26	73.2% upside
2025-11-06	Oppenheimer	$30	99.9% upside
2025-11-03	H.C. WainwrightRaghuram Selvaraju	$30	99.9% upside
2025-10-07	Oppenheimer	$25	66.6% upside
2025-09-30	Goldman Sachs	$7	53.4% downside
2025-09-30	NeedhamSerge Belanger	$20	33.2% upside
2025-09-30	Guggenheim	$20	33.2% upside
2025-09-29	Jefferies	$8	46.7% downside
2025-09-29	RBC Capital	$10	33.4% downside
2025-03-18	RBC Capital	$67	346.4% upside
2024-07-01	H.C. WainwrightRaghuram Selvaraju	$100	566.2% upside
2024-04-02	Goldman SachsRichard Law	$62	313.1% upside
2023-08-31	NeedhamSerge Belanger	$76	406.3% upside

MoonLake Immunotherapeutics (MLTX) FAQ

MoonLake Immunotherapeutics posts a target price of $48. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $48 for MLTX means covering analysts, on average, see the stock 216.5% upside of $15.01 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for MLTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; MoonLake Immunotherapeutics's other metric pages and overview cover the third.